Thursday, 19 November 2026 Tracking Indian retail every day
Healthcare Explainer

How Indian pharmacy chains make money

An evergreen explainer on how Indian pharmacy chains earn from dispensing, front-of-store retail, private label and diagnostics tie-ins, and why supplier credit and inventory turns decide profitability.

How Indian pharmacy chains make money

The short answer

Indian pharmacy chains earn from four overlapping streams: prescription dispensing, front-of-store retail of OTC and personal care products, private-label goods with higher margins, and diagnostics or online fulfilment tie-ins. Store-level profit depends on gross margin mix, pharmacist and rent costs, and how fast inventory turns using supplier credit as working capital.

Key takeaways

  • Indian pharmacy chains earn from prescription dispensing, front-of-store retail, private label, diagnostics tie-ins and online fulfilment, with front-of-store and private label carrying the wider margins.
  • Store-level profit depends on blended gross margin, pharmacist salaries, rent and inventory turns, not on sales alone.
  • Supplier credit is the hidden engine of expansion: chains collect cash at the counter before paying distributors, so slower turns turn credit into a cash trap.
  • Network profitability comes from central buying and spreading fixed costs like compliance, technology and distribution across many stores.
  • The metrics that matter in judging a chain are gross margin mix, turns by store cohort and days payable against days inventory — not store count.

A pharmacy chain business model in India is a retail business wearing a white coat. At its core, a chain buys medicines and health products from distributors and manufacturers, stocks them in a licensed store, sells them at a regulated or market price, and keeps the difference. What makes it different from a kirana store is that part of the sale — prescription medicine — is legally gated by a registered pharmacist, and part of it — vitamins, baby care, skincare, sanitisers — is ordinary retail where margin and impulse decide the outcome. Understanding how Indian pharmacy chains make money means looking at both halves together, because neither is profitable enough on its own.

Three terms matter from the start. Gross margin is what you keep after the cost of the goods sold, before rent, salaries and electricity. Inventory turns is how many times a year you sell and replace your stock. Supplier credit is the window a distributor gives you to pay, a general industry norm that varies by supplier and category. A pharmacy chain lives or dies on the gap between the credit it gets and the cash it collects at the counter.

How does a pharmacy chain make money on a single sale?

Break the counter down by basket type. A pure prescription basket — a strip of tablets, a syrup, an inhaler — usually carries a thin trade margin because scheduled medicines are price-controlled under the National Pharmaceutical Pricing Authority (NPPA) rules for scheduled formulations, and because the customer is not choosing on price. A front-of-store basket — a face wash, a pack of diapers, a protein powder, a thermometer — carries a wider margin, because brands compete for shelf space and the retailer can negotiate.

That is why chains push what the industry calls front-of-store or FMCG-plus-pharma mix. The prescription brings the footfall and the trust; the front-of-store sale brings the profit. A store that sells only medicines is a low-margin distribution point. A store that converts a mother picking up a child's antibiotic into a buyer of baby wipes, a thermometer and a hand wash is a retail business.

Why private label changes the maths

Private label means the chain sells products made for it under its own brand — generic paracetamol, its own sanitiser, its own multivitamin, its own diapers. The chain buys at manufacturing cost and sells at a retail price close to the branded equivalent, so the margin is far higher than on a third-party brand. It also builds customer loyalty, because the product exists only in that chain.

The trade-off is trust and capital. A private-label medicine must clear regulatory and quality expectations, and a private-label skincare product must earn repeat purchase without national advertising. Chains that get this right treat private label as a margin engine. Chains that get it wrong sit on slow stock.

What other revenue streams sit on top of the counter?

Modern Indian chains layer additional streams onto the same store and the same footfall.

  • Diagnostics tie-ins: a collection point or partner lab inside or next to the store, where the chain earns a commission or referral fee for samples collected. Point-of-care testing is a growing category — BabyCue, an Odisha-based healthtech startup, won first prize at the Tribal Business Conclave Open Grand Challenge for its DiaCue rapid diagnostic test, an award presented by President Droupadi Murmu. The company says DiaCue distinguishes bacterial from non-bacterial diarrhoea in 15 minutes, which points to the appetite for low-cost tests at the counter level.
  • Online fulfilment: the same inventory sold through an app or a marketplace, picked from the nearest store. This adds sales without adding rent, but it adds delivery cost, packaging and returns.
  • Brand activation and shelf fees: consumer health and personal care brands pay for visibility, end-caps and in-store promotion. This is small per store but meaningful across a network.
  • Wellness and consultation services: diet counselling, health checks and loyalty programmes that raise basket size.

What does it cost to run a pharmacy store in India?

The cost structure is where most of the story sits. Four lines decide whether a store is profitable.

  1. Cost of goods: the largest line. The blended gross margin depends on how much of the basket is prescription versus front-of-store versus private label.
  2. Pharmacist cost: a registered pharmacist must be present during operating hours, which means salary, shift cover and compliance. This is a fixed cost that does not fall when sales are slow.
  3. Real estate: rent and deposits for a high-street or hospital-adjacent location. Pharmacy footfall rewards visibility, and visibility costs rent.
  4. Working capital: the cash locked in stock, offset by supplier credit.

That last line is the quiet engine of the model. If a distributor gives a payment window of several weeks and the store sells the stock faster than that, the chain collects cash before it pays. That gap funds expansion — new stores are partly financed by the suppliers' balance sheets, not just the promoter's. When turns slow down, the same mechanism becomes a trap: the credit falls due while the stock sits on the shelf.

Worked example (hypothetical): Say a single store does monthly sales of ₹12 lakh. Prescription medicine is 60% of sales at a 16% gross margin, front-of-store is 30% at 28%, and private label is 10% at 45%. Blended gross margin works out to roughly 22.5%, or about ₹2.7 lakh a month. Rent is ₹55,000, two pharmacists and two counter staff cost ₹1.1 lakh, electricity and other overheads ₹35,000, and delivery plus packaging for online orders ₹20,000. Store-level operating profit is about ₹50,000 a month, or roughly 4% of sales. If inventory of ₹9 lakh turns six times a year against 45-day supplier credit, the store is cash-positive even at that thin margin. If turns drop to four times a year, the same store starts borrowing to pay suppliers. These figures are illustrative arithmetic, not observed industry data.

Why do some chains make money and others do not?

The difference is rarely the price of medicine. It is the mix and the discipline.

Mix: a chain that grows front-of-store and private label faster than prescription share lifts blended margin without raising prices. A chain that stays prescription-heavy competes on location and convenience alone.

Turns: fast-moving categories — pain relief, cough and cold, baby care, chronic-disease refills — should turn quickly. Slow categories like high-value devices or niche supplements eat cash. Good chains prune the tail of the SKU list ruthlessly.

Network effect: a chain buys centrally, so it negotiates better purchase terms than a standalone chemist. It also spreads fixed costs — compliance, technology, a pharmacist pool, a distribution centre — across many stores. That is what makes the network more profitable than the sum of its stores.

Common mistakes founders make

  • Counting revenue instead of blended gross margin. A store can grow sales and lose money.
  • Opening stores for footfall without checking whether the catchment has prescription demand or only walk-in traffic.
  • Ignoring the working-capital cycle. Supplier credit feels like free money until turns slow.
  • Launching private label in categories where trust is fragile and quality lapses are expensive.
  • Treating online orders as incremental revenue without loading the picking, delivery and return costs.

What questions do the unit economics raise for a chain?

Start with the unit economics, not the store count. The metrics that matter in judging a chain are gross margin mix, turns by store cohort and days payable against days inventory — not store count. A chain with a large share of gross margin and eight turns is a different business from one with a higher margin and four turns.

Then look at the pharmacist roster and licensing compliance per state, because a store cannot legally operate without one. Check the lease profile — how many stores are up for renewal in the next 24 months and at what escalation. Look at the private-label share of sales and whether it is growing on repeat purchase or on discounting. Finally, check the diagnostics and online contribution separately; both can look attractive at the top line while adding cost at the store.

What it means for Indian retailers

The pharmacy chain in India is not one business but a stack of them: a regulated dispensing counter, a convenience retail shelf, a private-label brand, a diagnostics referral point and a delivery node. Profitability at store level comes from mixing those streams so the thin-margin prescription sale pays for the footfall and the wider-margin front-of-store sale pays for the rent. Profitability at network level comes from central buying, shared fixed costs and a working-capital cycle that funds growth. Founders who treat the pharmacy as a medicine shop miss the retail half. Founders who treat it as a retail shop miss the licence, the pharmacist and the trust that makes the front-of-store sale possible in the first place.

In this story

Frequently asked questions

How do Indian pharmacy chains earn a margin on medicines?

Prescription medicines usually carry a thin trade margin, and scheduled formulations are price-controlled under NPPA rules. Chains make up for it through front-of-store products like skincare, baby care and supplements, and through private-label goods that carry much higher margins.

Why is supplier credit so important to a pharmacy chain?

Distributors generally extend a payment window, a common industry norm that varies by supplier and category. If a store sells its stock faster than that window, it collects cash before paying suppliers, and that gap funds new stores. If inventory turns slow, the credit falls due while stock sits on the shelf.

Do diagnostics tie-ins add meaningful revenue?

They add a commission or referral fee on samples collected, plus footfall. The size depends on the partner lab and the catchment. Low-cost point-of-care tests could in principle widen this stream at the counter level.

What decides whether a single pharmacy store is profitable?

Blended gross margin, rent, pharmacist and staff salaries, and inventory turns. A store with thin margins can still be cash-positive if stock turns fast against supplier credit; a high-sales store can lose money if turns slow.

Is private label risky for a pharmacy chain?

Yes. Private-label medicine and personal care must meet quality and regulatory expectations, and customers must trust the brand without national advertising. Done well it lifts margin; done poorly it leaves slow stock on shelves.

WiseRetail

The week in Indian retail, ecommerce and D2C — in one short email every Friday.